Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a history of moderate to severe plaque psoriasis for at least 6 months prior to Visit 1;~* Subjects with moderate to severe plaque psoriasis covering ≥10% body surface area (BSA), with a psoriasis area and severity index (PASI) ≥12 and static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2~Exclusion Criteria:~* History of discontinuation of biologic therapies (including marketed and investigational drugs) directly targeting Interleukin (IL)-17A, IL-17A/F, IL-17 receptor A, IL-12/IL-23p40 or IL-23p19 due to lack of efficacy, according to the Investigator's judgment;~* Prior exposure to retinoid-related orphan receptor (ROR)-γ inhibitors;~* Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions (e.g., clinically-significant eczema or severe acne) at Visit 1;~* History or presence of itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin within 12 months prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- JTE-451 Dose 1 (Type: EXPERIMENTAL): JTE-451 Tablets Dose 1 daily for 16 weeks.
- JTE-451 Dose 2 (Type: EXPERIMENTAL): JTE-451 Tablets Dose 2 daily for 16 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Tablets daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).